Moderna (MRNA) August 2 weekly 120 straddle priced into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Moderna stock plunges as guidance cut on low EU sales, U.S. vaccine competition
August 1, 2024 6:52 AM EDT(Updated - August 1, 2024 9:51 AM EDT)
Moderna (NASDAQ: MRNA) reported its second-quarter earnings Thursday, revealing a revenue of $241 million, a significant beat compared to the analyst consensus estimate of $128.41 million.
However, the company's stock plummeted by as much as 18% in early Thursday trading due to a downward revision in its full-year revenue guidance.
The biotechnology firm posted an adjusted EPS of -$3.33, narrowly outperforming the analyst estimate of -$3.35. While revenue beat expectations, it marked a 30% decrease from the $344 million reported in the same quarter last... More
